Estimating global treatment toxicity burden from adverse-event data.

Area of Science:

• Oncology
• Clinical Trials
• Biostatistics

Background:

• Current methods for summarizing treatment toxicity are inadequate, lacking differentiation by severity and type.
• A need exists for a standardized, clinically feasible measure to assess the global toxicity burden of medical treatments.

Purpose of the Study:

• To develop and validate a clinically feasible method for estimating the global toxicity burden of medical treatments.
• To create a Toxicity Burden Score (TBS) that accounts for toxicity severity, type, and organ class.

Main Methods:

• A prospective evaluation of toxicity profiles from a randomized clinical trial of 746 prostate cancer patients.
• Physician evaluation using visual analogue scales and mixed-effects models to derive TBS from 27 predictors.
• Analysis included severe (grade 3) and life-threatening (grade 4) toxicities across Common Terminology Criteria for Adverse Events organ classes.

Main Results:

• The TBS differentiated between toxicity grades and organ classes, with higher scores for infections, cardiovascular, and pulmonary events.
• Grade 4 events generally had higher TBS than grade 3 events, with exceptions noted for specific toxicity types.
• High intrarater (0.91) and moderate interrater (0.59) correlations indicate reliability of the TBS.

Conclusions:

• The Toxicity Burden Score (TBS) effectively summarizes global treatment toxicity, incorporating physician judgment.
• TBS distinguishes between severe and life-threatening toxicities and across different organ classes.
• This validated method provides a robust tool for comparing cancer therapies based on comprehensive toxicity assessment.